Sanofi

NASDAQ:SNY

Drug Manufacturers - General

Healthcare
$47.12 -0.73%

-$0.31 today

Market cap
$113.15B
Beta
0.28
P/E (TTM)
8.5
EPS (TTM)
$8.60
Dividend yield
5.62%
52W Low $41.86High $52.68

Volume 2.32M

Average 2.78M

SNY Net Income

Bottom-line profit after all expenses, interest, and taxes.

SanofiNASDAQ: SNY

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income declines year over year

Q2 FY2026 net income of €343M fell 91.3% year over year, behind the -56.6% change in trailing-twelve-month net income. Sequentially, it fell 78.7% from the prior quarter. Over 3 fiscal years it compounded at -2.3% a year.

Context

  • Net income amounted to 16.7% of revenue in FY2025, up 4.2 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 9 analysts of €10.04B (+28.5%) for the fiscal year ending Dec 2026, a slowdown from the +40.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
€343M-78.7% QoQ
Last fiscal yearDec 2025
€7.81B+40.5% YoY
LTMJun 2026
€3.96B-56.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-91.3%+20.2%+111.5 pp
1 year+40.5%+28.5%-12.0 pp
3-year CAGR-2.3%+13.9%+16.2 pp
5-year CAGR+11.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

EUR · from the income statement

Latest · FY2025
7.81B EUR
Year-over-year change
+40.5%
4-year CAGR
+5.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How SNY compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -56.6% is the 8th highest of 11, against a peer median of +10.9%.
  • Net income amounts to 8.1% of revenue for SNY, versus a peer median of 18.3%.
SNY Competitors
Net Income for SNY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 116.44B DKK+4.8%+22.6%35.3%
LLYEli Lilly and CompanyLTM Jun 2026$26.71B USD+93.6%+49.0%33.5%
NVSNovartis AGLTM Jun 2026$12.76B USD-6.6%+26.4%22.9%
AZNAstraZeneca PLCLTM Sep 2026$10.99B USD+16.9%+46.1%17.7%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$9.28B USD+83.8%+3.7%18.9%
AMGNAmgen Inc.LTM Jun 2026$8.74B USD+32.1%+5.6%22.9%
GSKGSK plcLTM Jun 2026£4.82B GBP+40.8%-27.4%14.5%
PFEPfizer Inc.LTM Jun 2026$4.33B USD-59.7%-37.2%6.8%
SNYSanofiLTM Jun 2026€3.96B EUR-56.6%-2.3%8.1%
MRKMerck & Co., Inc.LTM Jun 2026$3.17B USD-80.7%+7.9%4.8%
GILDGilead Sciences, Inc.LTM Jun 2026-$3.24B USD-151.3%+22.8%10.6%
Peer median (excluding SNY) —+10.9%+15.3%18.3%

Competitors are the stored peer set for SNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue39.18B40.56B41.62B44.29B46.72B
Cost of Revenue12.26B11.88B12.63B13.21B13.05B
Gross Profit26.92B28.68B28.99B31.08B33.67B
Gross Margin68.7%70.7%69.7%70.2%72.1%
Research & Development5.69B6.5B6.51B7.39B7.84B
Selling, General & Admin9.56B8.74B8.93B9.18B10.24B
Operating Expenses18.79B18.52B22.03B23.83B24.07B
Depreciation & Amortization3.35B3.11B4.43B3.59B5.68B
EBITDA11.54B13.51B11.39B11.03B12.48B
EBITDA Margin29.5%33.3%27.4%24.9%26.7%
Operating Income8.13B10.16B6.96B7.25B9.6B
Operating Margin20.7%25.1%16.7%16.4%20.5%
Interest Income3.13M168.96M530.5M457.53M331M
Interest Expense377.37M384.8M512.82M622.58M626M
Other Income / Expenses(289M)(170M)(845M)(494M)(3.58B)
Income Before Tax7.84B9.99B6.12B6.76B6.02B
Pre-Tax Margin20.0%24.6%14.7%15.3%12.9%
Income Tax Expense1.56B1.91B1.02B1.2B1.04B
Net Income6.22B8.37B5.4B5.56B7.81B
Net Margin15.9%20.6%13.0%12.6%16.7%
EPS (Basic)2.493.192.152.193.20
EPS (Diluted)2.493.182.152.193.20
Weighted Avg Shares2.51B2.5B2.5B2.5B2.44B
Weighted Avg Shares (Diluted)2.51B2.5B2.51B2.5B2.44B

Sanofi

NASDAQ:SNY

Intrinsic Alpha fair value

Locked

Current Price

$47.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.